Jena, Germany | 30 September 2021 | Carl Zeiss Meditec AG
The Supervisory Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) has agreed on a change in the Executive Board of the company. Dr. Ludwin Monz, who has been Chief Executive Officer of the company since 2010, will turn over his position to Dr. Markus Weber, currently member of the Executive Board of Carl Zeiss AG, on December 31, 2021. The transition is happening on the best of terms and at Dr. Monz’ own request.
Dr. Weber has more than 20 years of experience in various management and research and development functions within the ZEISS Group and, on the Executive Board of Carl Zeiss AG, is currently responsible for the Semiconductor Technology segment. Along with his new role as Chief Executive Officer of Carl Zeiss Meditec AG, Dr. Weber will remain on the board of Carl Zeiss AG, assuming the responsibilities of Dr. Monz on that board, who will leave the Executive Board of Carl Zeiss AG on December 31, 2021.
In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The other two members of the Executive Board, Justus Felix Wehmer and Jan Willem de Cler, will remain in their current positions.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of €1,335.5m in fiscal year 2019/20 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med